Woebot Health Names Health Technology Leader Monique Levy as Chief Commercial and Strategy Officer
San Francisco, CA, October 8, 2020 – Woebot Health announced today it has appointed Monique Levy to the newly-created position of Chief Commercial and Strategy Officer. Reporting to CEO Michael Evers, Levy is responsible for the growth and commercial success of the company’s proprietary therapeutic portfolio and measurement technologies that are designed to improve mental health. The appointment rounds out the company’s executive team, which also includes Founder and President Alison Darcy, Chief Clinical Officer Athena Robinson and Chief Technology Officer Casey Sackett.
Evers, who joined Woebot Health in March, said Levy’s formidable experience building businesses and innovating care and health will be instrumental to the company’s next stage of development. “Monique’s training in clinical psychology and experience across some of the world’s most innovative data, digital health and therapeutics businesses bring incredible value to our operations and team. Her ability to develop a clear strategy in complex markets, grow high-functioning teams and deliver excellence to partners make her the ideal executive to help drive rapid growth.”
Levy’s track record includes executive-level positions at some of the world’s leading bio, data and consumer health technology companies, where she worked with top scientists and technologists to develop novel products and innovative commercial partnerships. Before joining Woebot Health, Levy was Chief Strategy Officer at the precision CNS biotechnology company BlackThorn Therapeutics, where she led corporate and platform strategy as well as corporate development. Before that she was Global Head of Strategy, Partnerships and Products at the precision medicine company iCarbonX Group. Levy has also held executive-level positions at PatientsLikeMe and Decision Resources Group, and served on Google Health’s Advisory Board.
“My life’s purpose is to find ways to improve health, especially mental health, by leveraging technology and ingenuity,” said Levy. “Woebot Health is an extraordinary company in part because it has thought deeply about how to preserve the element of therapeutic alliance in a digital therapeutic. Our technology works and scales, and that makes this a very hopeful time for changing the status quo in mental health.”
Levy holds a Master of Science degree in Clinical Health Psychology from the Albert Einstein Medical School and Ferkauf Graduate School of Psychology at Yeshiva University and a Bachelor of Science degree in Foreign Service, Science Technology and International Affairs from Georgetown University.
About Woebot Health
Woebot Health was founded in 2017 to modernize psychotherapy for the way we live today. The company is pioneering a new class of digital therapeutics, combining the best psychotherapeutic tools, principles of therapeutic alliance, and advances in AI and Natural Language Processing (NLP) to make therapy more scalable and accessible, and to improve outcomes in mental health. Headquartered in San Francisco, Woebot Health is funded in part by venture capital firms New Enterprise Associates (NEA) and Jazz Venture Partners, L.P., with participation from Andrew Ng’s AI Fund. For more information, please visit Woebot Health or follow Woebot on Facebook, Twitter, and LinkedIn.